Accession Number:

ADA627549

Title:

Comparison of New Hemostatic Granules/Powders With Currently Deployed Hemostatic Products in a Lethal Model of Extremity Arterial Hemorrhage in Swine

Descriptive Note:

Journal article

Corporate Author:

ARMY INST OF SURGICAL RESEARCH FORT SAM HOUSTON TX

Report Date:

2009-02-01

Pagination or Media Count:

14.0

Abstract:

Background HemCon bandage HC and QuikClot granules QC have been deployed for the past 5 years for treating external hemorrhage in combat casualties. We examined efficacy and initial safety of three new hemostatic granulespowders in a swine extremity arterial hemorrhage model that was 100 fatal with army standard gauze treatment. The new products were com- pared with the most advanced forms of HC and QC products. Methods Anesthetized pigs 37 kg, n 46 were instrumented, splenectomized, and their femoral arteries were isolated and injured 6 mm arteriotomy. After 45 seconds free bleeding, a test agent WoundStat WS, super quick relief SQR, Celox CX or a control product HC or QC bead bags advanced clotting sponge plus was applied to the wounds and compressed with a large gauze for 2 minutes. Fluid resuscitation colloid and crystalloid was given and titrated to a mean arterial pressure of 65 mm Hg. Animals were observed for 180 minutes or until death. Computed tomography angiography was performed on survivors and tissue samples were collected form wounds for histologic examination. Results No differences were found in baseline measurements and pretreatment blood loss 17.4 mLkg or - 0.5 mLkg, mean or - SEM among groups. Advanced clotting sponge plus testing was halted after six unsuccessful attempts no hemostasis observed whereas other agents were tested each in 10 animals. Stable hemostasis was achieved in 10 WS, 7 SQR, 6 CX, and 1 HC subjects in each group, resulting in the recovery of mean arterial pressure and survival of the animals for 3 hours p less than 0.05, SQR or WS vs. HC.

Subject Categories:

  • Medicine and Medical Research
  • Stress Physiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE